We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+25.11%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.83B
AUM Growth
+$194M
Cap. Flow
-$79.7M
Cap. Flow %
-4.36%
Top 10 Hldgs %
49.54%
Holding
75
New
12
Increased
19
Reduced
26
Closed
13

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$49.3M
2
AZN icon
AstraZeneca
AZN
+$40.1M
3
AXSM icon
Axsome Therapeutics
AXSM
+$33.8M
4
GKOS icon
Glaukos
GKOS
+$28.7M
5
UTHR icon
United Therapeutics
UTHR
+$24.3M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$75.6M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$31.5M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$29.6M
4
QURE icon
uniQure
QURE
+$25.8M
5
INSM icon
Insmed
INSM
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 89.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LQDA icon
51
PUT
Liquidia Corp
LQDA
$7.51B
$5.68M 0.31%
+250,000
New +$5.42M
CDTX
52
DELISTED
Cidara Therapeutics
CDTX
$5.19M 0.28%
54,197
-196,834
-78% -$12.6M
IMNM icon
53
Immunome
IMNM
$2.56B
$5.11M 0.28%
436,051
-342,425
-44% -$3.41M
NXTC icon
54
NextCure
NXTC
$20.8M
$1.3M 0.07%
222,654
-1
-0% -$5
WVE icon
55
Wave Life Sciences
WVE
$1.14B
$1.25M 0.07%
170,943
+53,040
+45% +$429K
SRRK icon
56
Scholar Rock
SRRK
$5.86B
$1.17M 0.06%
31,410
+4,970
+19% +$174K
JBIO
57
Jade Biosciences
JBIO
$1.21B
$927K 0.05%
107,391
– –
IRON icon
58
Disc Medicine
IRON
$2.85B
$896K 0.05%
13,553
+6,241
+85% +$371K
BOLT icon
59
Bolt Biotherapeutics
BOLT
$7.63M
$733K 0.04%
137,721
– –
ACAD icon
60
Acadia Pharmaceuticals
ACAD
$4.35B
$572K 0.03%
+26,800
New +$634K
ESTA icon
61
Establishment Labs
ESTA
$2.71B
$442K 0.02%
10,787
-17,333
-62% -$708K
IMA
62
ImageneBio Inc
IMA
$63.2M
$260K 0.01%
31,884
-1
-0% -$13
CDTX
63
CALL
DELISTED
Cidara Therapeutics
CDTX
– –
-100,000
Closed -$4.87M
COGT icon
64
CALL
Cogent Biosciences
COGT
$6.91B
– –
-660,000
Closed -$4.74M
GPCR icon
65
Structure Therapeutics
GPCR
$3.46B
– –
-34,353
Closed -$712K
INZY
66
DELISTED
Inozyme Pharma
INZY
– –
-4,280,308
Closed -$17.1M
IWM icon
67
PUT
iShares Russell 2000 ETF
IWM
$80.3B
– –
-250,000
Closed -$53.9M
LLY icon
68
Eli Lilly
LLY
$1.07T
– –
-97,018
Closed -$75.6M
REPL icon
69
Replimune Group
REPL
$724M
– –
-1,806,529
Closed -$16.8M
REPL icon
70
PUT
Replimune Group
REPL
$724M
– –
-1,500,000
Closed -$13.9M
ROIV icon
71
CALL
Roivant Sciences
ROIV
$25B
– –
-1,000,000
Closed -$11.3M
RYTM icon
72
PUT
Rhythm Pharmaceuticals
RYTM
$7.28B
– –
-225,000
Closed -$14.2M
SNDX icon
73
Syndax Pharmaceuticals
SNDX
$1.82B
– –
-1,524,440
Closed -$14.3M
YMAB
74
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-2,194,278
Closed -$9.9M
MTSR
75
DELISTED
Metsera Inc
MTSR
– –
-36,191
Closed -$1.03M
1 2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2025 Portfolio in Review

As of Q3 2025, Sofinnova Investments held 75 positions worth $1.83B, up 12% from $1.64B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sofinnova Investments withdrew a net $79.7M in Q3 2025, closing 13 positions and reducing 26 holdings. Its most notable exit was Eli Lilly, an estimated $75.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Vertex Pharmaceuticals worth $46.2M.

  • Sofinnova Investments's largest Q3 2025 buy was Vertex Pharmaceuticals: 117,875 shares worth $46.2M.
  • Sofinnova Investments added most to AstraZeneca in Q3 2025, an estimated $40.1M increase.
  • Sofinnova Investments's biggest Q3 2025 reduction was Rhythm Pharmaceuticals, cutting an estimated $31.5M.
  • Sofinnova Investments fully exited Eli Lilly in Q3 2025, selling an estimated $75.6M.
  • Sofinnova Investments's ten largest holdings make up 50% of its $1.83B portfolio in Q3 2025.
  • Sofinnova Investments opened 12 new positions and closed 13 in Q3 2025.
  • Sofinnova Investments's portfolio value rose 12% quarter-over-quarter to $1.83B.

Based on Sofinnova Investments's 13F filing for Q3 2025, filed 14 Nov 2025.